Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study
Main findingResult — go to the resultOdds ratio 1.99 CI 0.55–5.34Authors' conclusion
In ESBL-E urinary septic shock, empiric treatment with a non carbapenem regimen, including systematically aminoglycosides, was not associated with higher mortality, compared to a carbapenem regimen.
Study context
- Population
- ICU patients with ESBL-E urinary septic shock
- Participants
- 156 patients
- Exposure
- Empiric carbapenem vs non carbapenem β-lactam regimen
- Carbapenemn = 69
- Non carbapenemn = 87reference
- Outcome
- Mortality
- Follow-up
- Day 30
Methodological detailspropensity-weighted, multicentre, 11 ICUs
- Propensity-weighted
- Multicentre
- 11 ICUs
Main finding
As reported in the abstract
Odds ratio
1.99
CI 0.55–5.34
P = 0.16
Events by group
Carbapenem vs Non carbapenem
OR 1.99 (CI 0.55–5.34); P = 0.16
Observational data: associations, not effects.
Further findings
Illness severity, resolution of septic shock, ESBL-E infection recurrence
- Similar in the two groups
Safety
Secondary C. difficile infection
- Comparable rates
Original publication
Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study. Ann Intensive Care. Published 24 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →